Financial Results - BioXcel Therapeutics

BioXcel Therapeutics Reports Third Quarter 2024 Financial Results. Form 10-Q. Q2. BioXcel Therapeutics Reports Second Quarter 2024 Financial Results. ... BioXcel Therapeutics …

CouponFollow Extension

$16
OFF

BioXcel Therapeutics Reports Third Quarter 2024 Financial Results

6 days from now

Nov 14, 2024 · The Company used $16.3 million in operating cash during the third quarter of 2024. Cash and cash equivalents totaled $40.4 million as of September 30, 2024. Conference …

marketscreener.com

$16
OFF

BioXcel Therapeutics Reports Third Quarter 2024 Financial Results

6 days from now

Sep 5, 2024 · The Company used $16.3 million in operating cash during the third quarter of 2024. Cash and cash equivalents totaled $40.4 million as of September 30, 2024. Conference Call …

gurufocus.com

$214
OFF

BioXcel Therapeutics Reports Q3 2024 Financial Results

6 days from now

Nov 15, 2024 · Key financial metrics show that BioXcel Therapeutics recorded net revenue of $214 thousand for the third quarter of 2024, a decrease from the previous year, attributed to …

businessinsider.com

$7
OFF

BioXcel Therapeutics Announces Pricing Of $7.0 Million

6 days from now

1 day ago · NEW HAVEN, Conn., Nov. 22, 2024 (GLOBE NEWSWIRE) -- BioXcel Therapeutics, Inc. (the “Company”) (Nasdaq: BTAI), a biopharmaceutical company utilizing artificial …

globenewswire.com

$64
OFF

Axsome Therapeutics Reports Third Quarter 2024 Financial Results …

6 days from now

Nov 12, 2024 · Net loss for the third quarter of 2024 was $64.6 million or $(1.34) per share, compared to a net loss of $62.2 million or $(1.32) per share for the comparable period in 2023.

yahoo.com

$17
OFF

Aileron Therapeutics Reports Third Quarter 2024 Financial Results …

6 days from now

Nov 14, 2024 · Third Quarter 2024 Financial Results Cash Position: Cash and cash equivalents as of September 30, 2024 , were $17.7 million , compared to $21.9 million as of June 30, 2024 .

prnewswire.com

FAQs about Financial Results - BioXcel Therapeutics Coupon?

How much money did bioxcel Therapeutics make in 2024?

Cash and cash equivalents totaled $40.4 million as of September 30, 2024. BioXcel Therapeutics will host a conference call and webcast today, November 14, 2024, at 8:00 a.m. ET to discuss its third quarter 2024 financial results. To access the call, please dial 877-407-5795 or 201-689-8722. ...

What time will bioxcel Therapeutics' financial results be released?

Conferencecallset for 8:00a.m.ETtoday NEW HAVEN, Conn., Nov. 14, 2024 (GLOBE NEWSWIRE) -- BioXcel Therapeutics, Inc. (Nasdaq: BTAI), a biopharmaceutical company utilizing artificial intelligence to develop transformative medicines in neuroscience, today announced its financial results for the third quarter of 2024. ...

Is bioxcel Therapeutics a biopharmaceutical company?

NEW HAVEN, Conn., Nov. 14, 2024 (GLOBE NEWSWIRE) -- BioXcel Therapeutics, Inc. (Nasdaq: BTAI), a biopharmaceutical company utilizing artificial intelligence to develop transformative medicines in neuroscience, today announced its financial results for the third quarter of 2024. ...

What did Axsome Therapeutics do in Q3 2024?

NEW YORK, Nov. 12, 2024 (GLOBE NEWSWIRE) -- Axsome Therapeutics, Inc. (NASDAQ: AXSM), a biopharmaceutical company leading a new era in the treatment of central nervous system (CNS) disorders, today announced financial results for the third quarter of 2024 and provided a general business update. ...

How do I contact bioxcel Therapeutics?

Visit www.fda.gov/medwatchor call 1-800-FDA-1088. You can also contact BioXcel Therapeutics, Inc. at 1-833-201- 1088 or [email protected]. Please see full Prescribing Information. About BXCL501 ...

How do I access a live call from bioxcel Therapeutics?

To access the call, please dial 877-407-5795 or 201-689-8722. A live webcast will be available on the Investors section of the corporate website, bioxceltherapeutics.com and a replay will be available for 90 days. BioXcel Therapeutics may use its website as a distribution channel of material information about the Company. ...